Cargando…
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
The advent of next-generation sequencing (NGS) has allowed for the identification of novel therapeutic targets for patients with uncommon cancers. It is well known that fusion translocations are potent driver of cancer pathogenesis and can render tumors exquisitely sensitive to matching targeted the...
Autores principales: | Adashek, Jacob J., Sapkota, Surendra, de Castro Luna, Rodrigo, Seiwert, Tanguy Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090142/ https://www.ncbi.nlm.nih.gov/pubmed/37041305 http://dx.doi.org/10.1038/s41698-023-00378-9 |
Ejemplares similares
-
Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020) -
Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021) -
STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020) -
Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report
por: Zhu, Lucheng, et al.
Publicado: (2022) -
STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)